A reporter gene can provide important information regarding the specificity and efficacy of gene or cell therapies. Although reporter genes are increasingly used in experimental and clinical studies, a highly specific yet nonimmunogenic reporter that can track genes and cells in vivo by multiple imaging technologies still awaits development. In this study, we constructed a versatile and nonimmunogenic reporter gene to noninvasively image gene expression or cell delivery by optical imaging, MRI, and small-animal PET. Methods: We cloned and expressed a membrane-anchored anti-polyethylene glycol (PEG) reporter that consists of the Fab fragment of a mouse anti-PEG monoclonal antibody, AGP3, fused to the C-like extracellular-transmembrane-cytosolic domains of the mouse B7-1 receptor. Binding of PEGylated probes (PEG-NIR797 for optical imaging, PEGsuperparamagnetic iron oxide for MRI, and 124 I-PEG for smallanimal PET) were examined in vitro and in vivo. In addition, we compared the specificity, immunogenicity, and probe toxicity of the anti-PEG reporter with the gold standard reporter gene, type 1 herpes simplex virus thymidine kinase (HSV-tk). Finally, we derived a humanized anti-PEG reporter and evaluated its imaging function in vivo with subcutaneous and metastatic tumor models in mice. Results: The cells or tumors that stably expressed anti-PEG reporters selectively accumulated various PEGylated imaging probes and could be detected by optical imaging, MRI, and small-animal PET. Importantly, the anti-PEG reporter displayed an imaging specificity comparable to the HSV-tk reporter but did not provoke immune responses or cause toxicity to the host. Furthermore, the humanized anti-PEG reporter retained high imaging specificity in vivo. Conclusion: The highly specific and nonimmunogenic anti-PEG reporter may be paired with PEGylated probes to provide a valuable system to image gene expression or cell delivery in experimental and clinical studies.
Key Words: polyethylene glycol; anti-PEG reporter; humanized anti-PEG reporter; PEGylated imaging probes; noninvasive imaging Noni nvasive imaging of reporter genes can provide information regarding the expression, location, and persistence of genes and cells in vivo. Ideally, the reporter gene should allow specific imaging but display minimal immunogenicity. Type 1 herpes simplex virus thymidine kinase (HSV-tk), regarded as a gold standard reporter gene, allows specific imaging of gene expression or transplanted cells by SPECT (1) and PET (2) . Unfortunately, the immunogenicity of HSV-tk (3) and the mutagenic potential of its probes (4) may limit its experimental and clinical use. Endogenous reporter genes such as the dopamine D 2 receptor (5) and the transferrin receptor (6) display low immunogenicity, but the fact that the D 2 receptor is also expressed in the brain stratum and in the pituitary glands (7) and the transferrin receptor is widely expressed in vivo (8) may limit their specificity. An optimal reporter gene that possesses high imaging specificity and low immunogenicity remains to be developed for human use.
Membrane-anchored antibodies are attractive for the development of highly specific and nonimmunogenic reporter genes (9) (10) (11) (12) . Antibody reporters can be designed to exhibit low immunogenicity by using antibodies derived from the species of interest. Humanized antibodies can minimize both humoral and cellular immune responses to allow repeated and persistent imaging of gene expression in humans. Furthermore, antibody-antigen pairs possess high specificity and affinity without interference from cellular factors.
We have previously generated an anti-polyethylene glycol (PEG) antibody that binds the repeating backbone (O-CH 2 -CH 2 ) 34 of PEG and can detect or clear PEGylated proteins, liposomes, and nanoparticles in vitro and in vivo (13) . PEG is a water-soluble, nontoxic, nonantigenic, and biocompatible polymer that has been approved by the Food and Drug Administration for human use (14) . PEGylation is a proven technology; many PEGylated probes, such as PEGylated superparamagnetic iron oxide (15) , PEGylated fluorescent probes (16) , and PEGylated chelating agents (17) , are in commercial or late-stage clinical trials. As the list of PEGylated probes continuously expands, an imaging strategy that uses PEGylated probes to image human or humanized anti-PEG reporters should possess great potential for clinical applications.
In this study, we developed a versatile and universal reporter based on the surface expression of an anti-PEG Fab fragment on cells (Fig. 1A) . We examined the surface expression and the function of the anti-PEG reporter and tested whether the anti-PEG reporter could be detected by optical imaging, MRI, or small-animal PET. We compared the imaging specificity, immunogenicity, and probe toxicity of the anti-PEG reporter with those of the HSV-tk reporter in mice. Finally, we tested if the humanized anti-PEG reporter could be used for in vivo imaging of subcutaneous and metastatic tumor models by small-animal PET and optical imaging, respectively. The humanized anti-PEG reporter imaging system is expected to provide a valuable tool for monitoring gene and cell delivery in humans.
MATERIALS AND METHODS

Cells and Animals
NIH 3T3 mouse fibroblasts and human HeLa cervical cancer cells were purchased from American Type Culture Collection. EJ human bladder carcinoma cells and CNL Chang liver cells were obtained from Academia Sinica. The cells were cultured in Dulbecco minimal essential medium (Sigma-Aldrich) supplemented with 10% heat-inactivated bovine calf serum, penicillin (100 units/mL), and streptomycin (100 mg/mL) at 37°C in a humidified atmosphere of 5% CO 2 . Female BALB/c nude mice (6-8 wk old) and female BALB/c mice (6-8 wk old) were obtained from the National Laboratory Animal Center, Taipei, Taiwan. All mice receiving radioiodinated probes were pretreated with Lugol solution (Sigma) in their drinking water for 2 d to block thyroidal uptake of free radioiodine (18) . All animal experiments were performed in accordance with institutional guidelines and approved by the Animal Care and Use Committee of the Kaohsiung Medical University. 
Generation of Anti-PEG Reporter-Expressing Cells
The V L -Ck and V H -C H 1 domains of the anti-PEG reporter were cloned from complementary DNA prepared from the AGP3 hybridoma (19) following a previously described method (10) . Primers used in the cloning of V L -Ck and V H -C H 1 are as follows: V L -Ck sense: 59-tgctggggcccagccggccgatattgtgttgacgcaggct-39; V L -Ck antisense: 59-ccgctcgagacactcattcctgttgaagct-39; V H -C H 1 sense: 59-gaagatctgaagtgcagctggtggagtct-39; and V H -C H 1 antisense: 59-caggtcgacagctggaatgggcacatgcag-39. The V L -Ck and V H -C H 1 genes were joined by a composite furin-2A protease cleavage site (20) and fused to the complementary DNA sequence encoding the C-like extracellular-transmembrane-cytosolic domains of the mouse B7-1 antigen (eB7) in the pLNCX-eB7 retroviral vector (10) to generate pLNCX-anti-PEG-eB7. A plasmid (pLNCX-anti-DNS-eB7) that encoded a membrane Fab with specificity for 5-(dimethylamino)naphthalene-1-sulfonyl chloride (DNS) (21) was constructed in an analogous fashion. EJ/anti-PEG or EJ/anti-DNS cells that stably expressed approximately equivalent levels of anti-PEG or anti-DNS reporters were generated by retroviral transduction as previously described (22) . Characterization of the EJ/anti-PEG or EJ/anti-DNS cells by Western blotting and by flow cytometry is described in the Supplemental Methods (supplemental materials are available online only at http://jnm.snmjournals.org).
Synthesis of PEG-NIR797 and 4-Arm 124 I-PEG-SHPP, 124 I-FIAU Imaging Probes
The protocols of probe syntheses are provided in the Supplemental Methods. 
T2-Weighted MRI of Anti-PEG Reporter In Vitro and In Vivo
EJ/anti-PEG and EJ/anti-DNS cells (3 · 10 6 ) were incubated with 48, 24, 12, and 6 mM PEG 2000 conjugated superparamagnetic iron oxide (PEG-SPIO, kindly provided by Yun-Ming Wang of the National Chiao Tung University, Taiwan) on ice for 30 min. After being washed with cold PBS, the PEG-SPIO labeled cells were collected by centrifugation (1,500 rpm) and imaged with a clinical 3.0-T MRI scanner (Sigma; GE Healthcare) equipped with a highresolution head coil. All samples were measured by a T2-weighted spin-echo sequence (repetition time, 2,500 ms; echo time, 90 ms).
For in vivo imaging, BALB/c nude mice bearing established EJ/ anti-PEG and EJ/anti-DNS tumors (300 mm 3 ) in their right and left hind leg regions, respectively, were intravenously injected with PEG-SPIO (10 mg of iron/kg of body weight). Pentobarbitalanesthetized mice were sequentially imaged at 1, 2, and 24 h after injection with a 7-T horizontal-bore magnet (Bruker Instruments). A T2-weighted spin-echo sequence (repetition time, 2,500 ms; echo time, 90 ms) was used for MRI.
In Vivo Imaging of Anti-PEG and HSV-tk Reporters by Small-Animal PET BALB/c nude mice bearing established EJ/anti-PEG and EJ/anti-DNS or EJ/TK (an EJ cell line expressing functional HSV-tk) tumors (200 mm 3 ) in their right and left hind leg regions, respectively, were anesthetized with halothane vapor and then intravenously injected with 3,700 kBq (in 100 mL) of 4-arm 124 I-PEG-SHPP or 124 I-FIAU. The mice were sequentially imaged at 4, 24, and 48 h after injection with a micro-PET R4 scanner (Concorde Microsystems), following an imaging protocol previously described (18) .
Immune Response to Anti-PEG and HSV-tk Reporter Proteins
The immunogenicity of the anti-PEG and the HSV-tk reporters was compared using a previously described protocol (22) . Briefly, BALB/c mice were intravenously injected with 20 mg of pLNCX (vector control, n 5 6), pLNCX-anti-PEG-eB7 (n 5 8), or pLNCX-HSV-tk (n 5 8). Preimmune and immune (day 10) sera (diluted 1:200 in PBS) were added to the wells of microtiter plates precoated with BALB 3T3 cells transfected with pLNCX, pLNCX-anti-PEG-eB7, or pLNCX-HSV-tk-eB7 (which codes for a membrane form of HSV-tk). Binding of antibodies on the cells was detected by enzyme-linked immunosorbent assay as previously described (22) . All readings were background-adjusted by subtracting the absorbance of the wells incubated with preimmune sera.
Construction of Humanized Anti-PEG Reporter
The anti-PEG reporter was humanized using a previously reported protocol with minor modifications (23) . Briefly, to select human framework sequences for complementarity-determiningregion grafting, we compared the V H and V L sequences of the anti-PEG Fab with the National Center for Biotechnology Information database of human immunoglobulin germline sequences in the variable and joining regions using the IgBLAST program (http://www.ncbi.nlm.nih.gov/igblast/). DP35-JH4 and A2c-JK2 were found to be the most homologous to the V H and V L of anti-PEG reporter, respectively. For construction of the humanized V L , the complementarity-determining regions of anti-PEG V L , determined by the rule of Kabat et al. (24) , was grafted onto human A2c-JK2. For construction of the humanized V H , the complementarity-determining regions and 1 FR3 residue (Ser73) of anti-PEG V H were similarly grafted onto DP25-JH4. The humanized anti-PEG V L and V H segments were synthesized by assembly polymerase chain reaction (23) . The pLNCX-human anti-PEG-eB7 plasmid and tumor cells expressing humanized anti-PEG reporters (EJ/human anti-PEG and Hela/human anti-PEG) were constructed as described above.
In Vivo Imaging of Human Anti-PEG Reporter
The human anti-PEG reporter was examined in both subcutaneous and metastatic tumor models in vivo. For imaging the subcutaneous tumor model, BALB/c nude mice (n 5 3) bearing established EJ/human anti-PEG and EJ/anti-DNS tumors (200 mm 3 ) in their right and left hind leg regions, respectively, were imaged by small-animal PET as described above.
For imaging the metastatic tumor model, BALB/c nude mice (n 5 3) were intravenously injected with Hela or Hela/human anti-PEG cells (5 · 10 6 cells). After 3 wk, the mice were intravenously injected with PEG-NIR797 fluorescent probes (2 mg/kg of body weight). Whole-body images and lung-tissue images of these mice were acquired by the IVIS50 optical imaging system (excitation, 760 nm; emission, 835 nm) at 48 h after injection.
Statistical Analysis
Differences in tumor uptake of PEG-NIR797 were compared by the signed rank test. Data were considered significant at a P value of 0.05 or less. The cytotoxicity of iodinated 4-arm PEG-SHPP and FIAU and the immunogenicity of anti-PEG and HSV-tk reporters were compared by 1-way ANOVA using InStat software (version 3.0; GraphPad Software) followed by the Student t test. Bonferroni adjustment was used to adjust the significance level for multiple (3) comparisons. A P value of no more than the Bonferroni-corrected significance level (0.05/3 5 0.0167) was considered significant.
RESULTS
Characterization of Surface Anti-PEG Reporter
We constructed a membrane-anchored Fab with specificity to PEG as a reporter gene, or anti-PEG reporter. The light chain (V L -C K ) is joined-through a furin cleavage site and 2A peptide (20) -to the heavy chain (V H -C H 1), which is itself fused to the C-like extracellular-transmembranecytosolic domains of the mouse B7-1 antigen (Fig. 1A) . A membrane-anchored Fab with specificity for DNS was constructed in an analogous fashion. The DNS Fab does not bind PEG and was used as a negative control reporter.
To analyze the anti-PEG and the control anti-DNS reporters, total cellular, membrane, and cytosolic proteins were separated by SDS-PAGE under reducing conditions and analyzed by Western blotting using antibodies to the hemagglutinin epitope present in the light chain (Supplemental Fig. 1A) , or to the c-myc epitope present in the heavy chain (Supplemental Fig. 1B) . Two protein bands with apparent molecular weights of approximately 26 and 50 kDa, corresponding to the light chain and the heavy chain of the anti-PEG reporter, respectively, were detected. Most of the membrane-anchored anti-PEG reporters were present as fully cleaved Fab fragments. A minor band of approximately 84 kDa, representing uncleaved V L -C K -furin-2A-V H -C H 1-B7, constituted only a small proportion of the fusion protein expressed on the cell membrane. These results indicate that correctly processed anti-PEG reporter was expressed on the plasma membrane. Similar expression of the anti-DNS reporter on EJ cells was also noted.
EJ/anti-PEG and EJ/anti-DNS cells were stained with a commercial PEG-quantum dot to assess the PEG binding activity of the anti-PEG reporter. As shown in Figure 1B , EJ/anti-PEG cells but not EJ/anti-DNS cells selectively bound PEG-quantum dot. For testing of whether functional anti-PEG reporters can be expressed in vivo, cell suspensions prepared from freshly resected EJ/anti-PEG or EJ/ anti-DNS tumors were stained with a hemagglutinin antibody or PEG-quantum dot. Figure 1C shows that EJ/anti-PEG and EJ/anti-DNS cells recovered from tumors retained expression of the respective reporters, but only EJ/anti-PEG cells displayed PEG-quantum dot binding activity. These results show that functional anti-PEG reporters were expressed on cell membranes in vitro and in vivo.
In Vitro and In Vivo Imaging of Anti-PEG Reporter
We tested 3 major mainstream imaging technologies for detecting the anti-PEG reporter: optical imaging, MRI, and PET. EJ/anti-PEG and EJ/anti-DNS cells were stained with PEG-NIR797, PEG-SPIO, or 4-arm 124 I-PEG-SHPP. Probe binding on cells was quantified by optical imaging, T2-weighted MRI, or g-counting, respectively. Figure 2A shows quantitative binding of PEG-NIR797 to EJ/anti-PEG or EJ/ anti-DNS cells in vitro. On average, signal intensity (defined as photons/s/cm 2 ) was 6.5-, 7.5-, and 9.8-fold stronger in the EJ/anti-PEG cells than in the EJ/anti-DNS cells after the addition of 0.5, 0.1, and 0.02 mM PEG-NIR797, respectively. Similarly, PEG-SPIO was selectively trapped by the EJ/anti-PEG cells at all concentrations examined (darker images in Fig. 2C ). The T2 signal intensity was reduced by more than 23% (range, ;23.1%294.1%) in EJ/anti-PEG cells, compared with EJ/anti-DNS cells. In line with the optical imaging and the MRI results, more than 55-fold (range, ;55-to 159-fold) of 4-arm 124 I-PEG-SHPP was retained on EJ/anti-PEG cells than on EJ/anti-DNS cells (Fig. 2E) . These data indicate that the anti-PEG reporter can trap various PEGylated probes for optical imaging, MRI, and PET.
To investigate whether the anti-PEG reporter could be noninvasively imaged in vivo, we intravenously injected PEG-NIR797, PEG-SPIO, or 4-arm 124 I-PEG-SHPP into BALB/c nude mice bearing subcutaneous EJ/anti-PEG and EJ/anti-DNS tumors. Whole-body images of the tumorbearing mice were acquired by optical imaging, T2-weighted MRI, and small-animal PET, respectively. Figure 2B shows that PEG-NIR797 probe was selectively retained at EJ/anti-PEG tumors but not at EJ/anti-DNS tumors. The nearinfrared signal lasted as long as 48 h after injection and clearly indicated the locations of the EJ/anti-PEG tumors. Fluorescent intensities in the region of interest were 9.0-, 10.9-, and 16.9-fold greater in the EJ/anti-PEG tumors than in the EJ/anti-DNS tumors at 4, 24, and 48 h, respectively (P , 0.028 for all time points). Similarly, PEG-SPIO was selectively retained in EJ/anti-PEG tumors, leading to markedly darker signals (a positive T2-weighted signal) in the EJ/anti-PEG tumors but not in the control EJ/anti-DNS tumors (Fig. 2D) . Finally, consistent with the in vitro tests, the 4-arm 124 I-PEG-SHPP preferentially accumulated in EJ/anti-PEG tumors (Fig. 2F ). On average, EJ/anti-PEG tumors accumulated 4.4-, 6.0-, and 10.4-fold more radioactivity than did EJ/anti-DNS tumors at 4, 24, and 48 h, respectively (Supplemental Fig.  2) . Though slight signals could initially be detected in the lung, liver, and kidney, these nonspecific signals faded over time whereas specific signals remained conspicuous in the EJ/anti-PEG tumors. Collectively, these results indicate that the anti-PEG reporter, when paired with PEGylated probes, is useful for noninvasive imaging in vivo by optical imaging, MRI, and PET. Comparisons Between Anti-PEG and HSV-tk Reporters HSV-tk is currently regarded as a gold standard reporter gene. We therefore sought to compare the imaging specificity, immunogenicity, and probe toxicity of the anti-PEG and HSV-tk reporters. EJ/TK was generated by retroviral transduction. Western blotting indicated that EJ/anti-PEG and EJ/TK cells expressed similar levels of anti-PEG or HSV-tk reporter proteins (Supplemental Fig. 3) . BALB/c nude mice bearing EJ/anti-PEG and EJ/TK tumors in their right and left hind legs were intravenously injected with 4-arm 124 I-PEG-SHPP or 124 I-FIAU. Specific targeting of radioiodinated probes was analyzed by small-animal PET. Figure 3 shows that 4-arm 124 I-PEG-SHPP selectively accumulated in EJ/anti-PEG tumors but not in EJ/TK tumors whereas 124 I-FIAU displayed the opposite specificity. Importantly, imaging specificity attained by the anti-PEG reporter was comparable to HSV-tk.
The immunogenicity of the anti-PEG and HSV-tk reporters was examined after hydrodynamic-based gene transfer of anti-PEG-or HSV-tk-encoding plasmids to BALB/c mice. We did not detect noticeable antibody titer in mice injected with anti-PEG-encoding plasmids (Fig. 4) . In line with previous reports (3), however, antibodies against HSV-tk were readily detected in the mice injected with HSV-tk-encoding plasmids, indicating that HSV-tk was indeed immunogenic.
To assess the safety of anti-PEG or HSV-tk imaging probes, we incubated iodinated 4-arm PEG-SHPP or FIAU with parental EJ, EJ/anti-PEG, EJ/TK, and CNL cells. Consistent with previous results indicating that PEG is a nontoxic polymer (14) , iodinated 4-arm PEG-SHPP (#125 mM) did not affect the survival of CNL, EJ, or EJ/ anti-PEG cells (Supplemental Fig. 4A ). In contrast, FIAU was considerably cytotoxic to CNL cells (inhibitory concentration of 50%, 65.9 mM). Moreover, FIAU induced more pronounced cytotoxicity to the cells that expressed HSV-tk (inhibitory concentration of 50%, 0.18 mM, P , 0.00001, comparing EJ/TK to EJ; Supplemental Fig. 4B) . These results and previous reports (15,16) firmly demonstrate that PEGylated probes display little toxicity to mammalian cells. On the contrary, the dose of HSV-tk probes should be carefully adjusted to prevent toxicity.
In Vivo Imaging of Humanized Anti-PEG Reporter
Before the anti-PEG reporter can be used in humans, the mouse-derived sequences must be humanized to minimize human antimouse immune responses. The complementarity-determining regions of the anti-PEG V H and V L were grafted onto the human germline DP-35 1 JH4 and A2c 1 JK2 segments to create humanized anti-PEG V H and V L (Supplemental Fig. 5 ). The humanized anti-PEG V H and V L genes were fused to human IgM C H 1 and Ck genes to construct the heavy chain and light chain of the humanized anti-PEG reporter (human anti-PEG). The human anti-PEG reporter was functional as shown by binding of PEGquantum dot to EJ/human anti-PEG cells (Fig. 5A) . As a test of its in vivo utility as a reporter gene, BALB/c nude mice bearing established EJ/human anti-PEG and EJ/anti-DNS tumors in their right and left hind legs, respectively, were intravenously injected with 4-arm 124 I-PEG-SHPP and then imaged with a small-animal PET scanner. Figure  5B shows that specific signals selectively accumulated at EJ/human anti-PEG tumors at 4 h after injection. The radiointensity of the region of interest was 4.5-, 5.0-, and 10.4-fold greater in the EJ/human anti-PEG tumors than in the EJ/anti-DNS tumors at 4, 24, and 48 h, respectively (similar to EJ/anti-PEG tumors vs. EJ/anti-DNS tumors). In addition, a metastatic lung model of Hela/human anti-PEG cells was also monitored by optical imaging. Figure 5C shows that specific fluorescent signals were detected in the lung foci after intravenous injection of Hela/human anti-PEG cells but not control Hela cells. Collectively, these results indicate that humanized anti-PEG may be an optimal reporter gene for noninvasive imaging of gene expression and cell delivery in humans.
DISCUSSION
Here we report a versatile and universal anti-PEG reporter to trap a wide range of PEGylated imaging probes. Selective retention of PEGylated probes at sites of anti- PEG reporter expression can facilitate monitoring of the delivery and expression of genes or cells in vivo by multiple imaging systems, including optical imaging, MRI, and PET. The anti-PEG reporter displayed an imaging specificity comparable to HSV-tk but did not provoke immune responses or cause apparent toxicity. The humanized anti-PEG reporter described here also facilitated effective and specific imaging in vitro and in vivo. Collectively, the anti-PEG reporter possesses high specificity and low immunogenicity, which may be useful for clinical optimization of gene or cell therapies in humans.
PEG is a nontoxic and biocompatible polymer that has been approved by the Food and Drug Administration for human intravenous, oral, and dermal applications (14) . Thus, increasing numbers of PEGylated molecules are in late-stage clinical trials or already approved for human use. In addition, PEG-coated liposomal doxorubicin (25) and PEG Interferon alfa-2b (26) can more effectively control diseases while reducing the injection frequency. As the number of PEGylated molecules expands, the anti-PEG reporter should help their rapid clinical translation.
The development of a versatile reporter that can be monitored by multiple imaging systems will extend its utility in biomedical research. Each imaging modality has inherent strengths and weaknesses. For example, nuclear imaging is highly sensitive but suffers from poor spatial resolution (27) . MRI has spectacular image resolution, but imaging sensitivity is inferior to that of nuclear techniques (28) . Optical imaging is relatively inexpensive but can be limited by the shallow depth penetration of the signal (29) . Because PEG can easily be linked to a wide variety of imaging probes (30) , the anti-PEG reporter allows flexibility in choosing the optimal imaging system. In addition, the anti-PEG reporter can efficiently bind even low concentrations of PEGylated probes (1 nM for PEGquantum dots), as long as the PEG chains are greater than 1.5 kDa (13) .
Efficient surface expression of the functional anti-PEG reporter can be attributed to 3 main factors. First, a Fab fragment rather than single-chain antibody was used. In most cases, an intact Fab fragment maintains higher binding affinity than a single-chain antibody (31) , because interactions across the V L /V H and C K /C H 1 domains can form a more stable structure than those between V L and V H domains alone (32) . Second, following a previously reported method (20) , we inserted furin-2A cleavage sites between the light-and heavy-chain genes to achieve efficient surface expression of the mature anti-PEG reporter from a single open reading frame. The light chain can be liberated from the nascent polypeptide to pair-through disulfide bonds-with the heavy chain to form a functional anti-PEG reporter in the endoplasmic reticulum. Third, the anti-PEG reporter is fused to the transmembrane domain and cytoplasmic tail of the B7-1 antigen, which was found to mediate rapid transport of chimeric protein to the cell surface (33) .
To increase the clinical utility of the reporter, we humanized the anti-PEG Fab to minimize human antimouse immune responses and thus allow repeated and persistent imaging of the reporter in humans. Importantly, humanization of the anti-PEG reporter did not hamper its activity; the humanized anti-PEG reporter displayed high imaging specificity in subcutaneous and metastatic tumor models in vivo as determined by smallanimal PET and optical imaging. A wide range of transmembrane domains derived from human proteins including the human B7-1 antigen have been used to anchor heterologous proteins on cells (9) , which will facilitate complete humanization of the human anti-PEG reporter. The human anti-PEG reporter, the first example of a humanized antibody used as a reporter gene, may provide a powerful tool for monitoring the efficacy of gene or cell therapy and survival of organ transplants in humans by multiple imaging systems.
The anti-PEG reporter may have widespread use in clinical and experimental medicine. The anti-PEG reporter may be transgenically expressed in specific tissues or organs to allow noninvasive imaging of disease progression. Alternatively, a transgenic mouse that ubiquitously expresses the anti-PEG reporter may serve as a syngeneic cell, tissue, or organ donor to study transplant survival in recipient (nontransgenic) mice by noninvasive imaging. Unlike other transgenic mouse models that use exoge- nously derived reporters (34), the anti-PEG reporter should not provoke immunity in nontransgenic recipients. Finally, the anti-PEG reporter may be useful for tracking the homing, migration, turnover, and transdifferentiation of stem cells on transplantation.
CONCLUSION
The anti-PEG reporter system possesses several advantages. The system has high affinity and specificity to allow stable retention of the probes at anti-PEG-expressing sites. The anti-PEG or human anti-PEG reporter can circumvent immune responses to allow repeated and persistent imaging of gene expression in mice or humans. PEG is a safe polymer approved by the Food and Drug Administration and can easily be linked to any suitable imaging probe to pair with multiple imaging systems. Because of these advantages, we believe that the anti-PEG reporter may provide a valuable tool to image the location and delivery of gene therapy or cell therapy, the progression of autoimmune diseases, and the survival of organ transplants in animals and humans.
